Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of CinnoVex vs Avonex in Healthy Volunteers
NCT03614715Phase 1Completed
- Sponsor
- CinnaGen
- Start
- Nov 2017
- Primary completion
- Feb 2019
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of interferon beta-1a in multiple sclerosis (MS) (2 arms), sponsored by CinnaGen. Primary endpoints: Area Under the Curve to the last measurable concentration at Day 8 and Maximum Plasma Concentration at Day 8. Started Nov 2017; status: completed.
02
Drugs
interferon beta-1a
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT03614715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03614715.